title: Treatment effects of selegiline transdermal system on symptoms of major depressive disorder: a meta-analysis of short-term, placebo-controlled, efficacy trials.
abstract: OBJECTIVE
  Selegiline transdermal system (STS) is efficacious for the treatment of major depressive disorder (MDD). This meta-analysis explores treatment effects of STS for individual symptoms of MDD derived from line-item analyses of the 28-item Hamilton Rating Scale for Depression (HAM-D28) and the Montgomery-Asberg Depression Rating Scale (MADRS).
  
  
  METHODS
  Change in score from baseline to end of treatment for each item of the HAM-D28 and MADRS was assessed using a multilevel model for meta-analysis of continuous outcome data from all five short-term, randomized, placebo-controlled efficacy trials conducted during preapproval clinical development of STS for MDD. Utilizing a random-effects model with trial effects fixed and adjusting for baseline scores, confidence intervals (95%) were computed for treatment differences between STS and placebo.
  
  
  RESULTS
  STS exhibited significant treatment effects on core depression symptoms (HAM-D Bech-6 items: depressed mood, guilt, work and activities, retardation, psychic anxiety, general somatic symptoms), reverse vegetative symptoms (oversleeping, overeating), motoric retardation, suicide, and genital symptoms (libido). Significant STS treatment effects were also noted for each MADRS item except for reduced sleep and appetite. The most prominent MADRS effects were improvement in sadness, lassitude, and poor concentration.
  
  
  CONCLUSIONS
  STS, an monoamine oxidase inhibitor antidepressant that potentiates the three major monoamine neurotransmitters (serotonin, norepinephrine, and dopamine), has beneficial therapeutic effects for a spectrum of individual symptoms rated by the HAM-D28 and MADRS. Analyses of specific symptoms assessed by depression rating scales can offer guidance to clinicians in individualizing drug therapy based on presenting symptoms.
authors.affiliation: Worldwide Drug Development, Burlington, VT, USA. dsrobmd@aol.com
authors.forename: Donald S
authors.initials: DS
authors.lastname: Robinson
authors.forename: Michelle L
authors.initials: ML
authors.lastname: Gilmor
authors.forename: Ying
authors.initials: Y
authors.lastname: Yang
authors.forename: George
authors.initials: G
authors.lastname: Moonsammy
authors.forename: Albert J
authors.initials: AJ
authors.lastname: Azzaro
authors.forename: Dan A
authors.initials: DA
authors.lastname: Oren
authors.forename: Bryan J
authors.initials: BJ
authors.lastname: Campbell
mesh_terms: D000279:Administration, Cutaneous; D000293:Adolescent; D000328:Adult; D000368:Aged; D000928:Antidepressive Agents / Q000008:administration & dosage*; D003865:Major Depressive Disorder / Q000188:drug therapy* / Q000523:psychology; D005260:Female; D006801:Humans; D008297:Male; D008875:Middle Aged; D008996:Monoamine Oxidase Inhibitors / Q000008:administration & dosage*; D010919:Placebos; D016032:Randomized Controlled Trials as Topic; D012642:Selegiline / Q000008:administration & dosage*
chemical_list: D000928:Antidepressive Agents; D008996:Monoamine Oxidase Inhibitors; D010919:Placebos; D012642:Selegiline